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RACIAL/ETHNIC DISPARITIES IN TYPE 2 DIABETES REMISSION AFTER  
 
BARIATRIC SURGERY 
 
JENNIFER LEE 
 
ABSTRACT 
 
Background:  Previous studies have shown that there are racial disparities in type 2 
diabetes (T2DM) remission following bariatric surgery, with African-Americans (AA) in 
particular experiencing a subsequent relapse.  In recent years, some have attributed these 
findings to racial differences in fasting insulin levels, with AA having higher levels, as 
increasing evidence for an alternate model of T2DM pathophysiology gains support.  In 
this model, basal hyperinsulinemia is considered a primary event in T2DM disease 
development, rather than a compensatory response to increased insulin resistance. This 
study aimed to compare glycemic outcomes after bariatric surgery in different races, 
namely African-Americans (AA), Hispanic-Americans (HA), and Caucasian-Americans 
(CA), and to determine whether there were any associated changes in insulin levels and 
insulin resistance that may lend support to this revised model of T2DM pathophysiology. 
Methods: A retrospective medical record review of 1,326 patients (389 AA, 179 HA, and 
758 CA) who underwent bariatric surgery at Boston Medical Center (BMC) from 2004 to 
2015 was conducted.  Baseline characteristics and maximum percent weight loss were 
compared using one-way ANOVA and Chi-square tests of independence. Changes in 
mean glycated hemoglobin (HbA1c), insulin levels, insulin resistance (HOMA-IR), and 
blood glucose levels were analyzed using linear mixed models, overall and by racial 
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group. The same procedures were conducted in both the overall patient population and a 
T2DM subpopulation. 
Results: Over an 11-year postoperative observation period, all racial groups underwent a 
significant decrease in HbA1c (P<0.001) within the first two years following surgery. 
While HbA1c levels remained stable in CA and HA, they began to rise at 2 years in AA 
only (P=0.043).  Additionally, analyses of covariates, including age at surgery (P=0.005), 
initial BMI (P<0.001), and maximum weight loss (P=0.049), revealed that all three were 
significant factors affecting mean HbA1c levels. However, when included in the mixed 
model, the race x time interaction effect on mean HbA1c remained significant. There was 
also a significant overall decrease in both insulin and HOMA-IR. When stratified by race, 
analysis of the T2DM population showed that insulin levels began to increase again by 
the 2
nd
 year after surgery in AA, while in CA and HA they continued to decrease and 
subsequently stabilize. Analysis of the total patient population showed that HOMA-IR 
levels in AA, as well as in CA and HA, continued to decrease at this 2-year time point. 
Decreases in blood glucose levels after surgery were significant overall (P<0.001), but 
not significant when stratified by race.  
Conclusions: After the initial “metabolic reset” that occurs within the first 2 years after 
bariatric surgery, during which HbA1c levels normalize in the vast majority of patients, it 
was observed only in the AA population that there was a steady increase in HbA1c to 
levels near those recorded at baseline. This coincided with an observation of increasing 
insulin levels despite decreasing insulin resistance seen in AA only. Our results suggest 
that current discussions regarding a revised model of T2DM pathophysiology, in which 
  vii 
hyperinsulinemia precedes insulin resistance, may help explain the racial disparities in 
glycemic control observed in both post-surgical and non-surgical contexts of T2DM 
outcome. However, future prospective studies are needed to further the preliminary 
results of this study. 
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 1 
INTRODUCTION 
 
Diabetes mellitus has become a growing public health concern in the United 
States over the past several decades.  From 1980 through 2012, the number of adults 
diagnosed with this disease has quadrupled to 21.3 million cases.  Following this trend, a 
third of all adults in the United States could be affected by the disease by the year 2050.
1
  
This represents a major burden on our public health resources due to the high prevalence 
of diabetes-related cardiovascular conditions.
2
  There is also an additional estimated 8.1 
million in the US who remain undiagnosed.
3
  Of those diagnosed, 90-95% have type 2 
diabetes mellitus (T2DM), which serves as the main point of focus among healthcare 
providers and public health officials, and thus this study.
4
 
 
The Pathophysiology of Type 2 Diabetes 
A. Current Model 
The current model of T2DM pathophysiology begins with the development of 
insulin resistance in the peripheral tissues, namely muscle and fat, and the liver.  Insulin 
resistance occurs when some environmental and/or genetic factors cause a reduction in 
insulin-stimulated glucose uptake by the peripheral tissues and an increase in glucose 
output from the liver.  Simultaneously, the pancreatic β-cells begin to hypersecrete 
insulin in a compensatory mechanism to maintain normal glucose levels in the body, 
resulting in chronically elevated fasting insulin levels, a condition known as  
hyperinsulinemia.
5
  Eventually, the β-cells begin to fail to secrete enough insulin to meet 
 2 
the increased demand, at which point hyperglycemia and the clinical symptoms of T2DM 
begin to manifest (Figure 1).
6
  
 
 
Figure 1: The current model of T2DM pathophysiology. 
 
 This model links the hyperinsulinemia and insulin resistance observed prior to the 
onset of T2DM in a hyperbolic relationship that defines the ability of the body to 
“dispose of” exogenous glucose.  This relationship, known as the “disposition index” 
(DI), was initially observed in a longitudinal study of non-diabetic Pima Indians with 
normal glucose tolerance (NGT).  Summarized in Figure 2, this study observed β-cell 
function, assessed by the acute insulin response (AIR) to glucose, relative to insulin 
sensitivity, which was assessed at a constant low level of insulin (M-low).  As both 
insulin sensitivity and insulin secretion decrease, the “Progressors” experience a shift 
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from a NGT state to an impaired glucose tolerance (IGT) state, and eventually to diabetes 
(DIA), while the “Non-progressors” maintain a NGT state.7  This long observed 
relationship between insulin sensitivity in the peripheral tissues and insulin secretion by 
the β-cells has solidified an association between the two factors, making it difficult to 
conceive them as separate variables in T2DM progression.
8
 
 
 
Figure 2: The hyperbolic relationship between insulin secretion and insulin sensitivity. 
Taken from Weyer et al.
7
 
 
This model of T2DM pathophysiology has had a paramount influence on the way 
we treat diabetic patients, from directly administering insulin to prescribing insulin 
 4 
secretagogues, which are medications that induce β-cell secretion of insulin, and insulin-
sensitizing medications.  Yet, despite the major strides in pharmacological therapies that 
have allowed diabetics the chance to maintain normal blood glucose levels, the rate of 
spread of this epidemic has not slowed down. 
9
  Thus, increasing concerns continue to 
surround this disease. 
 
B. Hyperinsulinemia vs. Insulin Sensitivity 
Despite the general acceptance of the above model, research has begun to 
highlight an apparent distinction between hyperinsulinemia and insulin resistance.  One 
of the earlier observations comes from studies of weight loss.  Obesity has long been 
associated with T2DM, with the two conditions often referred to as the “twin 
epidemics.”10  Since obesity tends to precede or worsen diabetes, studies of obese 
diabetics treated by diet have shown that weight loss, decreased food intake, and 
increased physical activity improve the management of this disease.
11–13
  Even just 
modest weight reduction results in improvements in insulin sensitivity and thus glycemic 
control.
14
  However, additional evidence has shown that while insulin resistance is 
reduced in obese diabetics who undergo weight loss, there is a more pronounced 
reduction in fasting, or basal, insulin secretion.
15
  In observing similar improvements in 
glycemic control, Heilbronn et al.
16
 also found that modest weight loss resulted in 
reduced fasting hyperinsulinemia, while acute glucose-stimulated insulin secretion 
improved.  Such studies of the metabolic effects of weight loss have indicated that 
changes in β-cell function may be independent of those in insulin resistance. 
 5 
 Further support can be drawn from more direct, interventional lines of study, such 
as animal experiments.  For example, by chronically exposing mice to high levels of 
insulin, Yang et al.
17
 observed the onset of insulin resistance and loss of pancreatic islets.  
In other studies, overexpression of murine insulin genes showed that hyperinsulinemia 
can precede insulin resistance and elevated blood glucose.
18,19
  Though less evidence is 
available from human trials, some data have offered similar conclusions.  In fact, several 
smaller studies have shown that administration of diazoxide, a drug that inhibits insulin 
secretion by the β-cells, resulted in improved glycemic control following lower basal 
insulin levels.
20,21
  Such manipulations of fasting insulin have indicated the potential for a 
causal effect of hyperinsulinemia on insulin resistance, rather than the reverse. 
Evidence from observational human studies also draws a line between the two 
factors that have in the past been quantified interchangeably.
22
  For instance, Weyer et 
al.
22
 found in a population of Pima Indians with normal blood glucose levels that high 
basal insulin was a significant predictor of developing T2DM, with differences in insulin 
resistance only explaining half of the variation seen in basal insulin.  In the separate Israel 
Study of Glucose Intolerance, Obesity and Hypertension, Dankner et al.
23
 found from a 
24-year follow-up of normoglycemic subjects that basal hyperinsulinemia was the 
strongest predictor of future dysglycemia.  Both studies have pointed to the likelihood of 
hyperinsulinemia, rather than insulin resistance, being the primary causative factor in the 
development and progression of T2DM.  Such findings have further elucidated this 
alternate view of T2DM pathophysiology.  However, of particular interest as of late has 
come from the observations made in human studies of bariatric patients. 
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Type 2 Diabetes and Bariatric Surgery 
In recent years, findings from bariatric surgery, also known as weight loss 
surgery, among diabetic patients have provided insight into another perspective of T2DM 
pathophysiology.  With increasing evidence that bariatric surgery is an effective long-
term treatment for obesity, its use has surged in recent years with 101,645 operations 
performed in the U.S. and Canada in 2011 alone.
24
  There has also been a major shift in 
attitude among physicians towards no longer just recommending bariatric surgery as a 
last resort for the morbidly obese.
25,26
  This is largely due to the mass of evidence 
collected over the past couple of decades which has shown that patients with Class III 
obesity who undergo surgery experience far more success in weight loss and 
improvement in obesity-related comorbid conditions, such as diabetes, hypertension, and 
dyslipidemia, than those who receive non-surgical treatment.
27
 
Of particular interest to us are the remarkably consistent findings on the resolution 
of T2DM in obese individuals undergoing surgery.  In cases of “resolution” or 
“remission” of T2DM, β-cell function and peripheral tissue insulin sensitivity are 
restored, no longer requiring patients to take anti-hyperglycemic medications.
28
  The 
Swedish Obese Subjects (SOS) study provides us with some of the first long-term 
observational data on weight loss and obesity-related comorbidities in bariatric subjects. 
Of the 2,010 diabetic bariatric subjects observed, 72% had short-term T2DM remission 
after 2 years and 36% retained long-term remission after 10 years.
29
  Finding similar, but 
more short-term results in a case-matched study of subjects who underwent the Roux-en-
 7 
y Gastric Bypass (RYGB) surgery and non-surgical controls, Dorman et al.
30
 also 
observed that diabetics who underwent surgery saw a significant reduction in the number 
of hyperglycemia-controlling medications required just 1 year after surgery.  In the 
Diabetes & Aging Study, Karter et al.
31
 found that in a community setting, it was 
extremely rare for diabetics who were medically managed to undergo remission within 5 
years beginning treatment, compared to the 70% of diabetics who underwent remission 
after receiving surgery.  In the Surgical Treatment and Medications Potentially Eradicate 
Diabetes Efficiently (STAMPEDE) trial, one of the only large-scale, long-term 
randomized controlled trials on the subject, obese diabetics receiving either the gastric 
bypass or sleeve gastrectomy experienced superior glycemic control 3 years after surgery 
to those who were only receiving medical therapy.  In addition, a significant proportion 
of those who underwent bariatric surgery no longer required anti-diabetes medications to 
control blood glucose levels.
32
  Similarly, in a review of bariatric procedures and their 
effect on metabolic conditions, Arterburn and Courcoulas
27
 analyzed 136 studies and 
reported an average T2DM remission rate of 72%.  Such consistent findings regarding the 
recovery of normal glycemic control have implicated bariatric surgery as an effective 
mode of T2DM treatment. 
However, what is most striking is that the vast majority of these studies and others 
alike is that this resolution of T2DM occurs quickly, before any significant weight loss is 
observed.  As a result, this has suggested endocrine mechanisms at work immediately 
following surgery.
33
  In a review, Pories and Dohm
34
 point out that in most of these 
studies of T2DM remission in bariatric patients, a correction of fasting hyperinsulinemia 
 8 
is also observed within a very short time after surgery.  They also note that this 
normalizing of basal insulin is independent of changes in glucose and free fatty acids, 
both of which affect insulin levels, insulin sensitivity, and body mass index (BMI), 
proposing that basal hyperinsulinemia is the primary change in this metabolic reset that 
occurs in response to surgery.  
 
Disparities in Post-Surgical Outcome 
While these findings continue to instill confidence in bariatric surgery as a 
potential long-term “cure” for T2DM, an increasingly apparent problem lies in the racial 
disparities we see in metabolic outcome after surgery.  Several studies have already 
established that African-Americans (AA) experience less excess weight loss after 
bariatric surgery than do Caucasian-Americans (CA) and Hispanic Americans (HA); 
there is also increasing evidence that AA experience less metabolic success as well.
35–37
  
In a study of bariatric patients in the Bariatric Outcomes Longitudinal Database (BOLD), 
Sudan et al.
38
 found that resolution of diabetes one year after surgery was less in AA than 
in CA and HA, who had similar metabolic outcomes.  In a study of AA, CA, and HA, 
Istfan et al.
39
 reported significant decreases in glycated hemoglobin levels (HbA1c), a 
measure of glycemic control, in all three racial groups, followed by a significant increase 
in HbA1c in only AA, indicating a relapse into T2DM.  While racial disparities in T2DM 
prevalence have been heavily documented in the past, these recent observations that AA 
are less likely to benefit from the anti-diabetic effects of bariatric surgery emphasize the 
need for more research in this area.
40
 
 9 
There have been several explanations as to why such disparities among patients 
with T2DM exist.  First, many have pointed to socioeconomic factors.  Golden et al.
41
 
stated that the overall lower socioeconomic status (SES) of AA, compared to CA, 
explains the disparate metabolic outcomes of conditions such as T2DM, despite similar 
incidence of disease.  Similarly, Link and McKinlay
42
 found SES to be much more 
strongly associated with T2DM prevalence than race, noting a potential reason as 
differences in access to quality care for disease prevention and management.  However, 
other studies have pointed out the opposite.  McWilliams et al.
43
 found that SES, in terms 
of health insurance coverage and access to quality care, was not associated with 
differences in diabetes outcome.  Additionally, a handful of studies of veterans have 
found that glycemic control and T2DM outcome remained worse in AA than in CA, even 
after controlling for socio-demographic factors.
44,45
  Such conflicting evidence has left 
the role of SES in the racially disparate outcomes of T2DM unclear. 
Other explanations apart from SES have been suggested in the causation of racial 
disparities.  For instance, it is known that AA have poorer glycemic control than CA.
46,47
   
This is notable in that several studies observing pre-surgical characteristics in diabetic 
bariatric patients have found that high pre-operative HbA1c levels are associated with 
failure of T2DM resolution after surgery.
48–50
  Several explanations have been proposed 
for the less optimal glycemic control observed in AA.  One of the most commonly 
discussed possible causes is that AA are more insulin resistant than other racial groups, a 
condition that could contribute to the poorer control of blood glucose levels.
51–53
  This 
explanation would hold true on the basis of the current model of T2DM pathophysiology 
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previously discussed.  However, other observations shed some doubt about this 
explanation.  For example, the fact that AA and HA have similarly high degrees of 
insulin resistance, when compared to CA, despite HA having better glycemic control.
54,55
  
Often referred to as the “Hispanic paradox,” this seems to suggest other factors, such as 
hyperinsulinemia, as the metabolic basis for racial disparities.
56
  In support of this 
explanation, it has long been observed that AA have higher basal insulin levels than do 
HA and CA.
54,57
   A study comparing AA and CA children of similar insulin sensitivity 
found AA children to be more hyperinsulinemic, and thus at higher risk of developing 
T2DM.
58
  The combined effect of greater insulin resistance and basal insulin secretion 
observed in AA compared to CA and HA, leads us to dissect the link between these two 
factors involved in T2D pathophysiology.  
 
Hyperinsulinemia in the Pathophysiology of T2DM 
This growing body of evidence from observational studies showing a separation 
of hyperinsulinemia and insulin resistance leaves room for alternate models of T2DM 
pathophysiology.  As previously discussed, the hypothesis suggesting hyperinsulinemia 
to be a cause of T2DM progression, rather than a compensation for insulin resistance, has 
gained support, through a couple of different proposed mechanisms.  In her 2011 Banting 
Lecture, Corkey proposed hyperinsulinemia as the primary etiologic factor in diabetes 
development resulting from an exogenous “Factor X” in diet.  Thus, she suggests that 
lowering of basal insulin secretion observed in certain individuals may be beneficial in 
stemming progression to T2DM.
9
   On the other hand, Pories and Dohm
34
 point at the 
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correction of hyperinsulinemia observed after bariatric surgery to propose that at least in 
some diabetics, there is an intrinsic dysfunctional “gut signal” to the pancreatic islets that 
causes upregulated β-cell function.  This increased secretion of insulin in the basal state 
eventually reaches a point where β-cells can no longer respond to food intake with any 
additional insulin secretion.  In another review, however, Shanik et al.
8
 suggest a 
mechanism of chronically elevated insulin levels leading to peripheral tissue 
desensitization to the hormone.  Nonetheless, this revised model, depicted in Figure 3, 
represents a novel way of thinking about T2DM and thus how we may go about treating 
this disease. 
 
 
Figure 3: The proposed model of T2DM pathophysiology. 
 
Given this background, we designed the current study to evaluate the racial 
differences in HbA1c, insulin resistance, and insulin levels in a racially mixed group of 
patients undergoing weight loss surgery at the Boston Medical Center (BMC).  While we 
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currently know that there are substantial metabolic improvements within the first two 
years following bariatric surgery, there is a lack of studies showing the long-term racial 
disparities in outcomes, particularly in glycemic control, after this period.  This study 
aims to examine the possibility that racial disparities in diabetes control and HbA1c 
levels after bariatric surgery could be predicted by higher basal insulin levels among AA.  
Achieving the goals of this study will provide strong support to the revised model of 
T2DM pathophysiology and further suggest novel treatment strategies for this chronic 
disease, especially in high-risk racial groups.   
 13 
Specific Aims and Objectives: 
The objective of the present study is to compare the degrees of success in type 2 
diabetes remission in different racial groups within the Boston Medical Center (BMC) 
bariatric patient population.  This will be conducted through retrospective analyses of 
patient data collected from electronic medical records (EMR).  Specifically, we aim to 
observe and compare the following variables in African-Americans, Hispanics, and 
Caucasians: 
 
1. Changes in glycated hemoglobin (HbA1c) levels in follow-up evaluations after 
bariatric surgery. 
2. Associated changes in insulin and glucose levels, and in insulin resistance over an 
11-year observation period. 
 
We hypothesize that, if African-Americans do experience less of the long-term 
optimal glycemic control after surgery compared to Hispanic- and Caucasian-Americans, 
this may be attributed to their higher levels of fasting insulin that exist prior to surgery 
and later following surgical intervention.  We will test this hypothesis by focusing on the 
metabolic changes noted in the medical records of patients who have had weight loss 
surgery at BMC between 2004 and 2015.  We will utilize the results from this study to 
help design a prospective clinical research project with the long-term objective of 
understanding the pathophysiologic role of hyperinsulinemia in racial disparities and 
diabetes treatment. 
 14 
METHODS  
 
Patients 
For this study, a retrospective electronic medical record (EMR) review of patients 
who underwent bariatric surgery at the Boston Medical Center (BMC) from 2004 through 
2015 was conducted.  The specific bariatric procedures these patients underwent included 
the Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy, and adjustable gastric band 
(see Appendix for brief descriptions of procedures).  Follow-up care was provided by the 
same clinic team during the observation period of this study.  Subjects removed from 
analysis included those who underwent surgical revisions and those who became 
pregnant.  The remaining records of 1,516 adult bariatric patients were included.  This 
study was approved by the BMC Institutional Review Board. 
 
Clinical Data 
Data were extracted from patients’ EMRs by the BMC Clinical Data Warehouse.  
The records collected included patients’ demographic characteristics (age at surgery, 
gender, self-reported race); pre-surgical weight and BMI; baseline blood test results, 
including HbA1c, glucose, insulin, and lipid levels; and prior medical history for 
diagnoses of T2DM, hypertension, dyslipidemia, obstructive sleep apnea, and arthritis.  
Also extracted were weights and any available blood test results from follow-up clinic 
visits. 
 
 
 15 
Statistical Analyses 
The main objectives of this study were to observe and compare the changes in 
glycemic control over an extended period of time following bariatric surgery, as well as 
the associated changes in insulin levels and insulin resistance, in different races.  This 
was done by conducting separate linear mixed model analyses for repeated measures in 
HbA1c, glucose levels, insulin levels, and insulin resistance.  The linear mixed model 
approach was utilized to permit analyses of longitudinal data with multiple variables and 
randomly missing information.  Comparisons among different races were made by 
observing a fixed race x time interaction. The mixed model procedure was performed 
first without any covariates, followed by analyses exploring the multiple effects of age at 
surgery, initial BMI, and maximum percent weight loss. 
Patients’ baseline characteristics were compared among racial groups by 
ANOVA, using Tukey’s honest significant difference (HSD) for multiple comparisons.  
Chi-square tests of independence were used for comparing prevalence of co-morbid 
conditions and use of different bariatric procedures among racial groups.  “Baseline” was 
defined as the closest record prior to surgery for each patient.  The maximum percent 
weight loss after surgery was determined by dividing the difference between initial 
weight and lowest post-surgical weight by the initial weight.  Insulin resistance was 
quantified by the homeostatic model assessment-estimated insulin resistance (HOMA-
IR), which was calculated from the formula: fasting insulin (IU/L) x fasting glucose 
(mg/dL)/405.
59
  However, since records infrequently specified whether insulin and 
 16 
glucose levels were fasting, any available insulin and glucose levels were utilized in our 
calculations. 
The same procedures were conducted for the T2DM subpopulation separately as 
well.  Analyses of type 2 diabetics was conducted by including patients with a pre-
surgical HbA1c > 6.0%. 
Statistical significance for all tests were defined by P<0.05.  All statistical 
analyses were performed using IBM SPSS Statistics Version 20. 
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RESULTS 
 
The total patient population of this study consisted 1,326 patients, including 389 
AA (29.3%), 179 HA (13.5%), and 758 CA (57.2%).  An additional 190 records listed 
under a diverse “Other” race category were excluded from further analyses of the study.  
The population examined had a mean age of 46±0.3 years (all mean values are presented 
with standard error), with females comprising 78.1%.  The mean pre-procedure weight 
was 278.2±1.8 lb and the mean initial BMI was 46.3±0.2 kg/m
2
.  The mean maximum 
percent weight loss after surgery was 29.8±0.3%.  The population had obesity-related 
comorbid conditions as follows: 74.5% with T2DM, 48.5% with dyslipidemia, 37.2% 
with obstructive sleep apnea (OSA), 72.0% with hypertension, and 12.1% with arthritis.  
As for specific bariatric procedures undergone by these patients, 85.6% had RYGB, 7.6% 
had the sleeve gastrectomy, 6.7% had the adjustable gastric band, and 0.2% had a gastric 
band-to-RYGB conversion. Patient characteristics broken down by racial group are 
presented in Table 1.  
Maximum percent weight loss varied significantly between the 3 racial groups 
(P=0.025), with AA losing less weight than CA (P=0.026).  Baseline BMI and glucose 
levels did not vary significantly by racial group.  Comorbid conditions that varied 
significantly between racial groups were as follows: AA had a greater percentage of 
diabetics than did both HA and CA (P<0.001); CA had higher prevalence of dyslipidemia 
than AA and HA (P<0.001); AA had a greater prevalence of hypertension than HA and 
CA (P<0.001); and AA had a greater prevalence of arthritis than HA and CA (P<0.001). 
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Table 1: Characteristics of all patients by race. 
  
African-
Americans 
Hispanic-
Americans 
Caucasian-
Americans 
Total Significance 
  
n=389 (29.3%) n=179 (13.5%) n=758 (57.2%) n=1,326 (P<0.05) 
Age (years) 45±0.5 41±0.7 48±0.4 46±0.3 <0.001* 
Sex (%) 
Female 88.9
b,c
 79.9
a
 72.0%
a
 78.1% <0.001 
Male 11.1% 20.1% 28.0% 21.9% 
 
Initial weight (lb) 274.9±3.1 263.3±4.6
c
 283.4±2.4
b
 278.2±1.8 <0.001 
Initial BMI (kg/m
2
) 47±0.5 45.0±0.6 46.0±0.3 46.0±0.3 0.157 
Maximum % weight 
loss 
28.5±0.6
c
 30.5±0.8 30.4±0.4
a
 29.8±0.3 0.025 
HbA1c (%) 7±0.1 6.0±0.2 7.0±0.1 7.0±0.1 0.158 
Insulin (IU/L) 24.8±1.5
c
 32.4±3.4 32.3±1.8
a
 30.0±1.2 .013 
Glucose (mg/dl) 120.9±2.9 117.7±3.5 127.6±2.6 124.0±1.7 .070 
HOMA-IR 7.8±0.7
c
 9.7±1.2 11.3±0.8
a
 10.0±0.5 .012 
T2DM (%) 82.9% 75.0% 66.6% 74.5% <0.001* 
Dyslipidemia (%) 48.4% 38.9% 51.8% 48.5% <0.001* 
OSA (%) 38.4%
b,c
 35.5%
a
 36.6%
a
 37.2% .208 
Hypertension (%) 79.2%
b,c
 65%
a
 67.7%
a
 72.0% <0.001 
Arthritis (%) 13.6%
b
 7.1%
a,c
 12.5%
b
 12.1% <0.001 
Bariatric 
procedure: 
(%) 
RYGB  82.2%
b,c
 92.4%
a,c
 86.4%
a,b
 85.6% 
<0.001 
SG  10.5%
b,c
 3.7%
a,c
 6.3%
a,b
 7.6% 
Band  7.4%
b
 3.9%
a,c
 7%
b
 6.7% 
Band to 
RYGB 
0.0% 0.0% 0.4%
a,b
 .2% 
BMI=body mass index; HbA1c=glycated hemoglobin, HOMA-IR=homeostatic model 
assessment-estimated insulin resistance; T2DM=type 2 diabetes; OSA=obstructive sleep 
apnea; RYGB=Roux-en-Y gastric bypass; SG=sleeve gastrectomy; Band=adjustable 
gastric band; Band to RYGB= Band to RYGB conversion 
Data are mean values ± standard error. 
*All pairs were significant 
a. Significant versus African-Americans 
b. Significant versus Hispanic-Americans 
c. Significant versus Caucasian-Americans 
 
 
A subpopulation of 803 (60.6%) individuals with T2DM was observed in this study 
as well.  This included 269 (33.5%) AA, 110 (13.7%) HA, and 424 (52.8%) CA.  The 
breakdown of the diabetic patient population characteristics by race is shown in Table 2.  
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Within the diabetic population, baseline HbA1c was actually higher in CA compared to 
AA (P=0.004), as was baseline insulin (P=0.011).  CA also had a higher baseline glucose 
level than both AA (P=0.002) and HA (P=0.009), as well as a higher insulin resistance 
than AA (P=0.002). 
 
Table 2: Characteristics of the diabetic patient population by race. 
  
African-
Americans 
Hispanic-
Americans 
Caucasian-
Americans 
Total Significance 
  
n=269 (33.5%) n=110 (13.7%) n=424 (52.8%) n=803 (P<0.05) 
Age (years) 47.0±0.6 43.0±0.9 50.0±0.5 48.1±0.4 <0.001* 
Sex (%) 
Female 85.1 81.8 67.5 75.3% 
<0.001 
Male 14.9
c
 18.2
c
 32.5
a,b
 24.7% 
Initial weight (lb) 278.4±3.9
b
 256.8±4.9
a,c
 284.1±3.3
b
 278.5±2.3 <0.001 
Initial BMI (kg/m
2
) 47.0±0.6 45.0±0.7 46.0±0.4 46.3±0.3 0.224 
Maximum % weight 
loss 
27.9±0.7
b
 30.9±1.0
a
 29.1±0.6 28.9±0.4 0.050 
HbA1c (%) 7.0±0.1
c
 7.0±0.2 8.0±0.1
a
 7.3±0.1 0.003 
Insulin (IU/L) 27.0±2.0
c
 30.8±4.1 37.7±2.8
a
 32.8±1.7 .014 
Glucose (mg/dl) 132.4±3.9
c
 129.0±5.0
c
 151.1±4.1
a,b
 140.9±2.6 .001 
HOMA-IR 9.2±0.9
c
 10.1±1.5 15.1±1.4
a
 12.2±0.8 .002 
Dyslipidemia (%) 45.7% 60.3% 5360.0% 64.3% <0.001* 
OSA (%) 31%
c
 34.6% 38.1%
a
 35.7% .001 
Hypertension (%) 71.9%
c
 69.9%
c
 82.6%
a,b
 76.0% <0.001 
Arthritis (%) 6.1%
b,c
 14.3%
a
 14.2%
a
 13.1% <0.001 
Bariatric 
procedure: 
(%) 
RYGB  93.6%
b,c
 86.7%
a
 84.4%
a
 86.7% 
<0.001 
SG  2%
b,c
 6%
a,c
 9%
a,b
 6.8% 
Band  4.4% 6.8% 6.6% 6.3% 
Band to 
RYGB 
0.0% 0.5%
a,c
 0.0% 0.2% 
BMI=body mass index; HbA1c=glycated hemoglobin, HOMA-IR=homeostatic model 
assessment-estimated insulin resistance; T2DM=type 2 diabetes; OSA=obstructive sleep 
apnea; RYGB=Roux-en-Y gastric bypass; SG=sleeve gastrectomy; Band=adjustable 
gastric band; Band to RYGB= Band to RYGB conversion 
Data are mean values ± standard error. 
*All pairs were significant 
a. Significant versus African-Americans 
b. Significant versus Hispanic-Americans 
c. Significant versus Caucasian-Americans 
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HbA1c Analyses: 
Mixed model analyses showed that there was a significant change in mean HbA1c 
over time for both the entire population (P<0.001) and for the diabetic population 
(P<0.001), as shown in Figures 4A and 4B, respectively.  In the total population, there 
was an overall significant decrease in mean HbA1c of 1.2± 0.1 percentage points 
beginning at 3 months post-surgery (P<0.001) continuing to a decrease of 1.4±0.1 at 1.5 
years (P<0.001).  At 2 years, there was an increase in mean HbA1c of 0.2± 0.1 (P=0.01).  
In diabetics, there was an overall significant decrease in HbA1c of 1.2± 0.1 percentage 
points beginning at 3 months (P=0.003) continuing to a decrease of 1.4±0.2 at 1.5 years 
(P<0.001).  At 2 years, mean HbA1c increased by 0.1± 0.2 (P=0.01).    
 
 
Figure 4: Changes in mean HbA1c over time in the (A) overall patient population and 
the (B) T2DM population.  Time points represent the following time ranges: -1= before 1 
yr pre-surgery; 0=1 yr pre-surgery1 week post- surgery; 1=1 week 1 month; 2=1 
month6 months; 3=6 months12 months; 4=12 month18 months; 5=18 
months24 months; 6=24 months30 months; 7=30 months39 months; 8=39 
months45 months; 9= after 45 months. 
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When race was included in mixed model analysis, changes in mean HbA1c over 
time (race x time interaction) were significant in both the entire population (P=0.034) and 
the T2DM subpopulation (P=0.04).  Figure 5A shows a summary of these results 
separated by race for those with T2DM.  Within diabetics, HbA1c in AA decreased by as 
much as 1.1± 0.2 percentage points by 1 year post-surgery (P=0.001), similar to the 
decreases observed in CA and HA.  However, after 2 years, HbA1c in only AA exhibited 
a significant increase of 0.3±0.2 (P=0.043) from the lowest HbA1c at 1 year.  As shown 
in Figure 5A, this trend of increasing HbA1c continues on over the remainder of the 
observation period. 
   Incorporating covariates into the mixed model, age at surgery, initial BMI, and 
maximum weight loss were significant factors in T2DM patients.  Age contributed 
positively to HbA1c by 0.0063 percentage points per year (P=0.005).  Initial BMI had an 
overall negative effect by decreasing HbA1c by 0.022 (P<0.005).  Maximum percent 
weight loss had an overall negative effect by decreasing HbA1c by 0.005 (P=0.049).  
After controlling for these three factors, the mixed model fixed effects of race, time, and 
race x time on mean HbA1c remained significant.  The adjusted means of HbA1c over 
time, accounting for these three factors, are shown in Figure 5B. 
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Figure 5: Changes in mean HbA1c over time by race in patients with T2DM only. (A) 
Mean values due to the effects of race over time. (B) Mean values adjusted for fixed 
effects of age, initial BMI, and maximum percent weight loss. Time points are the 
same as in Figure 3. 
 
Insulin Analyses: 
Mixed model analysis of mean insulin levels in T2DM patients showed an overall 
significant change over the observation period of 7 years following bariatric surgery 
(P<0.001).  There was a significant decrease of 21.5±7.1 IU/L (P=0.003) beginning 1 
year after surgery up to a decrease of 25.7±10.9 IU/L (P=0.019) at 5 years after surgery.  
This trend is shown in Figure 6A.  When race is factored into the mixed model, there is 
no significant difference in the changes in mean insulin levels over the observation period 
(P=0.703).  However, the fixed effect of the race x time interaction mixed model does 
reveal a significant change in AA in the first two years following surgery, as shown in 
Figure 6B.  After an initial decline at 1 year post-surgery, as seen in CA and HA, mean 
insulin levels in AA increase significantly by 3.9 IU/L from 16.11±5.8 IU/L at 1 year 
(P=0.022) to 20.0±10.5 IU/L at 2 years (P=0.015) post-surgery.  Similar results were 
observed in the total patient population that included non-diabetics.  In this group, there 
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was an overall significant change in mean insulin levels over the observation period 
(P<0.001).  Mean insulin levels decreased significantly by 17.9±2.9 IU/L at 1 year post-
surgery (P=0.003) up to an overall significant decrease of 22.1±8.8 IU/L at 5 years post-
surgery (P=0.019).  However, while the race x time interaction showed similar effects on 
mean insulin level to those in the T2DM group, the effect was not significant. 
 
 
Figure 6: Changes in mean insulin levels by year after surgery in (A) the overall T2DM 
patient population and (B) the T2DM population by race.  The box in (B) shows the 
period of significance in changes of mean insulin levels.  
 
 
Insulin Resistance Analyses: 
Overall, linear mixed model analysis of HOMA-IR score showed significant 
changes over time (P<0.001) in T2DM patients, as summarized in Figure 7A.  There was 
a significant decrease beginning with a mean HOMA-IR of 4.6±1.6 at 1 year post-surgery 
(P=0.003) to 1.7±5.1 at 5 years (P=0.017).  When race was included in the mixed model, 
the decreases observed across racial groups in mean HOMA-IR score were not significant 
by the fixed effects of either race alone or the race x time interaction.  However, there 
was a significant change in HOMA-IR in AA of the overall patient population, including 
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both diabetics and non-diabetics, within the first 2 years post-surgery (Figure 7B).  In 
AA, HOMA-IR score decrease by 0.8±3.5 between the first and second years after 
surgery (P=0.04).  There were also decreases in HOMA-IR in CA and HA of 0.2±3.3 and 
1.4±2.9, respectively, over the same time frame. 
 
 
Figure 7: Changes in mean HOMA-IR score over time in (A) all T2DM patients and (B) 
all patients by race.  The box in (B) shows the period of significance in changes of 
HOMA-IR. 
 
 
Glucose Analyses: 
Mean blood glucose levels in the total patient population decreased significantly 
over a 7-year observation period after surgery (P<0.001).  The lowest mean glucose level 
observed was 88.7±7.5 mg/dl at 4 years post-surgery (P=0.24), a 35.3±7.7 mg/dl decrease 
from baseline.  There was a similar decrease of 47.9±11.9 mg/dl glucose observed in the 
T2DM population, but the overall change in mean blood glucose over time was not 
significant.  Furthermore, mixed model analyses of a race x time interaction showed no 
significant effects on mean blood glucose in either the overall patient population 
(P=0.792) or the T2DM population (P=0.702).  
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DISCUSSION 
 
 The primary aim of this study was to compare the degrees of long-term glycemic 
control following bariatric surgery in different racial groups.  We also sought to observe 
the associated changes in insulin levels over an extended period of time.  We 
hypothesized that, if African-Americans do indeed undergo a relapse into diabetes, 
following an initial post-surgery remission, it may in part be explained by their higher 
basal insulin levels both prior to and after surgery.   
The results of this study regarding glycemic control, measured by HbA1c, in the 
bariatric population as a whole concurred with those of other studies showing an overall 
drastic improvement over the first few  years following surgery.
27,29–31
  However, given 
our study’s extended period of observation, we were able follow HbA1c values beyond 
this common short-term period of analysis. The design of the study using mixed model 
analysis also allowed us to observe different outcomes of glycemic control over time by 
race.  We therefore found our results to be consistent with those of Istfan et al.,
39
 showing 
that HbA1c levels in only AA return to near-preoperative levels, indicative of T2DM 
relapse, after the initial remission within the first 2 years following surgery.  The results 
of this study confirm that, while all racial groups undergo the initial “metabolic reset” 
soon after surgery, a certain proportion of patients, notably AA, does not experience the 
same long-term anti-diabetic benefits of bariatric surgery.  Specific metabolic 
characteristics, probably related to race, appear to play a role in the etiology of these 
differences. 
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We have previously noted that this racial disparity in post-surgical metabolic 
outcome might be related to differences in basal insulin levels.  AA have been reported to 
have higher basal insulin levels and insulin resistance than CA.
52
  However, the 
observation of the Hispanic Paradox – that HA have similarly high insulin resistance yet 
maintain more optimal glycemic control – is consistent with the interpretation that 
hyperinsulinemia is a potential culprit in T2DM pathophysiology.
54–56
  Furthermore, this 
separation of hyperinsulinemia from insulin resistance in T2DM progression has been 
gradually gaining support in other studies previously discussed.  This includes studies of 
weight loss showing the significant reduction of fasting insulin in diabetics, independent 
of improvements in insulin sensitivity.
11–13
  This also includes animal studies showing 
that overexpression of the insulin gene can lead to insulin resistance and drug studies 
demonstrating an improvement in glycemic control in individuals given insulin secretion 
inhibitors.
17–21
  And lastly, this includes long-term follow-up studies of normoglycemic 
individuals that found hyperinsulinemia to be a major independent predictor of the 
development of dysglycemia.
22,23
  Findings from such studies have allowed us to consider 
basal hyperinsulinemia to be the primary dysfunction preceding the onset of T2DM. 
Our second main objective of this study was to test the hypothesis that increases 
in basal insulin levels precede the changes in insulin resistance and could explain the 
worsening of HbA1c specifically among the AA patients two years after weight loss 
surgery.  Our results revealed that overall insulin levels and insulin resistance were 
consistent with other studies showing major decreases in both following bariatric surgery. 
However, multivariate analysis allowed us to observe the effects of race on each of the 
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two factors.  Within our total patient population, there was a significant decrease in 
insulin resistance, as measured by HOMA-IR, in all 3 racial groups within the first 2 
years following surgery.  While there were no significant changes in insulin levels within 
the same group, there was an increase in insulin levels in the T2DM population during 
the same time interval.  In the T2DM patients, this increase in insulin levels was observed 
only in AA, while in CA and HA insulin levels continued to decline and stabilize.  This 
coincided closely with the 2-year time point around which AA began to lose maintenance 
of normal glycemic control, as HbA1c levels rose.  This observation, while preliminary, 
is consistent with our hypothesis that hyperinsulinemia contributes to the 
pathophysiology of T2DM, especially in AA patients. 
It is important to note, however, that parameters used in this study were purely 
clinical in nature, which implies an inherently high degree of variation in values, as the 
“fed” or “fasting” states were not specified.  Thus, calculations of HOMA-IR, which 
require fasting insulin and glucose values, may not be reliable, as both these values varied 
greatly in the clinical data available.  There has also been speculation about the 
inappropriate use and overall accuracy of the HOMA model as of late.  While the original 
model (HOMA1), used in the present study, has been useful for examining longitudinal 
changes in insulin sensitivity and β-cell function, its developers have agreed that it has 
become increasingly outdated since it was calibrated for insulin assays specifically used 
in the 1970s.  There has since been the development of a newer computer-based model 
(HOMA2), not used in this study, that has been recalibrated to more accurately represent 
insulin sensitivity and β-cell function and may be useful for future studies.60  Further 
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assessments of the validity of HOMA1  have pointed out that the disposition index (DI), 
which is the product of insulin sensitivity (22.5/fasting insulin*fasting glucose) and β-cell 
function [20*fasting insulin/(fasting glucose – 3.5)] actually only depends on fasting 
glucose, whereas HOMA2 DI actually factors in insulin.
61
 Thus, while these major 
limitations do not permit us to definitively reach any conclusions, it is worth exploring 
the idea that higher insulin levels, even in the postoperative state, may explain a loss of 
glycemic control, independent of insulin resistance. 
The results of the present study regarding changes in insulin levels and insulin 
resistance are consistent with observations by Pories and Dohm,
34
 who have pointed out 
in numerous studies that reduction in insulin levels seen after bariatric surgery often 
occur independently of improvements in insulin sensitivity.  Our findings also agree with 
Reed et al,
62
 who observed that correction of fasting hyperinsulinemia was the most 
pronounced and early change that occurred in individuals who experienced T2DM 
remission following RYGB surgery.  These authors attributed their results to the 
likelihood of hyperinsulinemia being a primary event in T2DM progression.  Thus, if AA 
are more likely to relapse after the initial remission period following surgery, as 
confirmed in the present study, could this then be explained by the eventual failure of AA 
to maintain the corrected hyperinsulinemia?  The unequal metabolic outcomes following 
bariatric surgery observed in this and other studies emphasize the need for further 
prospective clinical research in this area.  Ultimately, this would lead to improved 
treatment modalities for this disease, especially in high-risk patient populations.  
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In addition to the main observations made in this study, there were other results 
worthy of further discussion.  First, our results from the multivariable analyses were 
consistent with findings from other studies.  The covariates we explored, including age, 
pre-surgical BMI, and maximum % weight loss, all had significant impacts on mean 
HbA1c, our index for glycemic control.  Our results showing a positive association 
between age and HbA1c has also been observed in studies of non-diabetic 
populations.
63,64
  However, this may simply be due to older individuals having had 
T2DM for a longer duration, which has been associated with worse post-surgical 
outcome in terms of remission.
48
  This may explain our baseline characteristics of T2DM 
patients, showing that our CA population was the oldest and also had the highest initial 
HbA1c.  Our finding that lower initial BMI was associated with a lower reduction in 
HbA1c is consistent with Dixon et al.,
49
 who concluded that a lower initial BMI actually 
resulted in a smaller post-surgery reduction in HbA1c and thus recommended caution in 
considering surgical treatments for these patients.  Additionally, in our patient population, 
maximum weight loss was positively associated with reduction in HbA1c. This is 
consistent with a study by Hamza et al.,
65
 in which % excess body weight loss was found 
to predict T2DM remission.  This can likely be explained by the decrease in caloric 
intake and adiposity, which ultimately improves insulin sensitivity.
28
  However, when we 
controlled for all 3 of these factors in multivariate analysis, the racial disparities in 
glycemic control after surgery persisted, further strengthening our findings of the 
importance of race in determining clinical outcomes after weight loss surgery. 
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Other important findings in the present study were noted in the patient 
population’s baseline characteristics.  For example, initial HbA1c, insulin levels, and 
HOMA-IR, were all significantly higher in CA than AA, which was contrary to what was 
expected and published in other studies.
52
  However, this may be due to the fact that there 
were disparate numbers of individuals in each racial group, with CA composing over half 
of the entire patient population.  Also, it may be possible that these values were simply 
higher because there were more data available in the CA group for subjects in a non-
fasting state, which was not specified in EMR. However, our results on maximum weight 
loss were consistent with other published findings that show AA losing less weight after 
surgery compared to CA, further highlighting the racial disparities in post-surgical 
outcome.
35–37
 
The strengths of this study lie in the large size and diversity of the patient 
population, which allowed us to compare different racial groups.  Also, a longer period of 
observation in this longitudinal data allowed us to follow subjects beyond the usual time 
frame of observation of 1-2 years, so that we could observe a delayed T2DM relapse that 
is not shown in many other studies. 
There are also, however, several notable limitations of this study.  First is that it 
was a retrospective rather than controlled prospective study.  Second, the study relied 
entirely on clinical data from EMRs.  Both these limitations meant that time points at 
which data were available varied in frequency and that the key variables in the study, 
including insulin and HbA1c, may not have been collected from patients in the fasting 
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state.  Thus, future prospective studies are necessary to provide answers for the questions 
we addressed in the current study.   
An additional limiting factor in the current study is that actual medication use was 
not used in the analyses.  We also did not control for the socioeconomic status or 
behavioral difference with which we could account for some of the racial disparities 
noted in this study.  Finally, in order to maximize statistical power, we analyzed data 
collectively for all the different surgical procedures, despite the fact that multiple studies 
have found RYGB to be more successful than other bariatric procedures in its anti-
diabetic effects.
27
  Thus, once again, we stress the need for future prospective studies on 
this subject to account for these variations and provide more accurate, meaningful data. 
 
 
Conclusion 
 
 Despite limitations, this study’s findings of racial differences in glycemic control 
after weight loss surgery are important because they allow us to better identify and target 
specific patients who are at higher risk of diabetes relapse.  While there were major 
limitations with accuracy inherent in clinical data, this study’s results provide preliminary 
support for future studies investigating the potential primary role of hyperinsulinemia in 
the onset of type 2 diabetes.  Furthermore, the understanding of racial disparities in 
metabolic outcomes after bariatric surgery is crucial for guiding healthcare professionals 
in decision making about long-term treatment options for patients with obesity and 
T2DM.  Of particular importance is the fact that finding a link between basal insulin 
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secretion and the progression of T2DM will doubtlessly lead to novel and more effective 
treatment paradigms for this chronic disease. 
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APPENDIX 
The most common bariatric procedures are Roux-en-Y gastric bypass (RYGB), 
adjustable gastric banding (GB), and the sleeve gastrectomy (SG) (Figure 8).  In RYGB, 
the stomach is divided into upper and lower portions, the former of which is anastomosed 
to the jejunum, a distal portion of the small intestine.  Thus, the lower portion of the 
stomach and the proximal portion of the small intestine, the duodenum, are bypassed by 
food.  In GB, a saline-filled band is wrapped around the upper portion of the stomach to 
restrict food passage into the rest of the gastrointestinal tract.  The size of the opening 
through which food may enter the stomach is controlled by injection or withdrawal of 
fluid in the band.  In SG, the size of the stomach is greatly reduced by essentially 
removing the body of the stomach from the tract  through a vertical transection.
66
 
 
 
 
 
Figure 8: The three most commonly performed bariatric procedures. (A) Roux-en-Y 
gastric bypass (RYGB); (B) Gastric band (GB); (C) Sleeve gastrectomy (SG). Taken 
from Neff and le Roux.
66  
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